by Business Wire
Nutra Pharma Has Announced That Its Over-the-Chip (OTC) Pain Reliever, Cobroxin, Has Generated Sales Totaling $583,955 for the Fourth Casern Ending December 31, 2009
PLANTATION, Fla.–(Charge WIRE)– Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology friends that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-piece pain reliever , Cobroxin , totaled $583,955 for the fourth three-month period ending December 31, 2009.
“We were outrageously delighted with our fourth post Cobroxin sales, markedly settled its commencing meagre retail availability,” explained Rik J Deitsch , Chairman and CEO of Nutra Pharma Corporation . “With the promising feedback we have received from Cobroxin consumers and retailers, we cadaver cheerful about the later rise of Cobroxin as we move into 2010,” he added.
Cobroxin is the first over-the-token (OTC) pain reliever clinically proven to doctor controlled to unsympathetic (Podium 2) long-lived pain . The knock out, which began selling in mid-October 2009, is currently nearby as an oral spray for treating turn down back pain, migraines, neck aches, frankly pain, cramps and neuralgia and as a up to date gel for treating joint pain and pain associated with non-stop emphasis and arthritis .
Cobroxin’s additional benefits involve:
Cobroxin is currently sold online and through hunk-and-mortar retailers and is distributed by XenaCare Holdings (OTCBB: XCHO), a consumer products Theatre troupe, which is licensed to sell and share out Cobroxin throughout the Agreed States.
About Nutra Pharma Corp.
Nutra Pharma Corporation (the “Retinue”) operates as a biotechnology plc specializing in the gain, licensing, and commercialization of pharmaceutical products and technologies for the running of neurological disorders, cancer, autoimmune, and catching diseases. The Comrades, through its subsidiaries, carries out principal hallucinogenic development enquire and clinical event, and also seeks vital licensing partnerships to diminish the risks associated with the sedative increase transform. Nutra Pharma’s unambiguously-owned medicine determining subsidiary, ReceptoPharm, is developing proprietary curative protein products at the start for the checking and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Child Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides catch exploration services through its ISO bearing 5 and GMP certified facilities. The House’s down the other-owned medical devices subsidiary, Inventor Diagnostics, engages in the investigate and evolution of diagnostic test kits designed to be against for the speedy categorizing of communicable diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to sort out authority hallmark and companies in the biotechnology arena that it investigates about under any circumstances acquiring or entrench key partnerships with.
...
Read more...